Benzinga | Oct 4, 2021 08:36AM EDT

Stifel Maintains Buy on Sage Therapeutics, Lowers Price Target to $75

Stifel analyst Paul Matteis maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and lowers the price target from $95 to $75.